๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA ยท Real-Time Price ยท USD
5.24
+0.28 (5.65%)
Nov 18, 2026, 12:35 PM EST - Market open

Entrada Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
3.9825.42210.78129.01--
Revenue Growth
-93.53%-87.94%63.38%---
Gross Profit
-129.07-115.1585.4829.13-66.61-35.93
Operating Income
-169.26-15647.01-3.16-97.25-51.13
Net Income
-161.39-143.7565.63-6.69-94.62-51.16
Earnings Per Share
-3.84-3.471.68-0.20-3.02-8.16
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
193.02295.7420351.97188.71291.06
Total Debt
47.3150.9359.2168.2325.94-
Net Cash (Debt)
145.7244.77360.79283.74162.78291.06
Net Cash Growth
-46.91%-32.16%27.16%74.31%-44.08%645.46%
Net Cash Per Share
3.475.929.258.595.2046.44

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-136.33-128.51-41.56139.8-93.79-50.86
Capital Expenditures
-0.01-1.04-3.16-5.61-2.89-4.58
Free Cash Flow
-136.33-129.55-44.72134.19-96.67-55.44
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
--40.55%22.58%--
Operating Margin
-4256.05%-613.66%22.30%-2.45%--
Pretax Margin
-4053.16%-561.84%31.54%9.34%--
Profit Margin
-4057.98%-565.48%31.14%-5.18%--
FCF Margin
-3428.06%-509.63%-21.21%104.01%--

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
--9.33---
P/FCF Ratio
---3.75--
PS Ratio
45.5314.502.903.90--